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Abstract
Background: Microglia-associated inflammation is closely related to the pathogenesis of various retinal diseases such
as uveitis and diabetic retinopathy, which are associated with increased vascular permeability. In this study,
we investigated the effect of systemic lipopolysaccharide (LPS) exposure to activation and proliferation of retinal
microglia /macrophages.
Methods: Balb/c and Cx3cr1gfp/+ mice were challenged with LPS (1 mg/kg) daily for four consecutive days. For
microglia depletion, mice were treated with colony-stimulating factor 1 receptor (CSF-1R) inhibitor PLX5622
1 week before the first LPS challenge and until the end of the experiment. In vivo imaging of the retina was
performed on days 4 and 7 after the first LPS challenge, using optical coherence tomography and fluorescein
angiography. Flow cytometry analysis, retinal whole mount, and retinal sections were used to investigate microglia and
macrophage infiltration and proliferation after LPS challenge. Cytokines were analyzed in the blood as well as in the
retina. Data analysis was performed using unpaired t tests, repeated measures one-way ANOVA, or ordinary one-way
ANOVA followed by Tukey’s post hoc analysis. Kruskal-Wallis test followed by Dunn’s multiple comparison tests was
used for the analysis of non-normally distributed data.
Results: Repeated LPS challenge led to activation and proliferation of retinal microglia, infiltration of monocyte-derived
macrophages into the retina, and breakdown of the blood-retina barrier (BRB) accompanied by accumulation
of sub-retinal fluid. Using in vivo imaging, we show that the breakdown of the BRB is highly reproducible but
transitory. Acute but not chronic systemic exposure to LPS triggered a robust release of inflammatory mediators in the
retina with minimal effects in the blood plasma. Inhibition of the CSF-1R by PLX5622 resulted in depletion of retinal
microglia, suppression of cytokine production in the retina, and prevention of BRB breakdown.
Conclusions: These findings suggest that microglia/macrophages play an important role in the pathology of retinal
disorders characterized by breakdown of the BRB, and suppression of their activation may be a potential therapeutic
target for such retinopathies.
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Background
Endotoxin-induced uveitis (EIU) is an animal model of
human uveitis, which can be induced by either a single
systemic or a local injection of lipopolysaccharide (LPS).
LPS is a component of the outer membranes of gram-
negative bacteria and has been shown to bind to
Toll-like receptor 4 (TLR4) in iris endothelial cells [1]
with subsequently increased inflammatory mediators
leading to break down of the blood–ocular barrier,
which in turn leads to edema and leukocyte influx [2, 3].
In the retina, expression of TLR4 is upregulated in the
inner nuclear layer (INL) and the ganglion cell layer
(GCL) after ischemia-reperfusion in rats [4]. Moreover,
in vitro studies using rat retinal pigment epithelium
(RPE) cells have shown that LPS treatment can lead to a
decrease of transepithelial electrical resistance and in-
creased RPE permeability [5]. In the posterior segment
of the eye, a single LPS injection leads to increased ad-
hesion of leukocytes in the retinal vascular endothelium
and activation of retinal microglia [6].
Microglia are the resident innate immune cells in the
central nervous system (CNS). In the retina, they are
mainly localized in the inner and outer plexiform layer
where they have surveillance function with a highly
ramified phenotype [7]. Upon activation, they undergo
morphological transformation and adopt an amoeboid
phenotype resembling activated macrophages. Microglia,
as well as blood inflammatory cells, such as monocytes
and neutrophils, play a critical role in the immune sys-
tem and are commonly activated in response to inflam-
matory conditions. Microglia/macrophages are activated
and increased in number as a result of both the prolifer-
ation of resident microglia and recruitment of circulat-
ing myeloid cells that infiltrate the retina after injury or
infection [8–10]. Microglial over-activation and subse-
quent inflammation are considered to be implicated in
the progression of retinal diseases such as age-related
macular degeneration (AMD), or diabetic retinopathy
(DR). Specifically, in mouse models of DR, upregulation
of inducible nitric oxide synthase (iNOS) has been posi-
tively correlated to the disruption of the blood-retina
barrier (BRB), since BRB breakdown was prevented in
iNOS deficient mice [11–14]. iNOS is mainly expressed
by cells such as macrophages, microglia, and astrocytes
in response to inflammatory stimuli such as LPS or cyto-
kines [15, 16]. Moreover, microglia/macrophages accu-
mulation in the sub-retinal space has been reported in
rodent models of DR [17], while inhibition of microglia’s
activation led to a reduction of proinflammatory cyto-
kines production in the diabetic retina [18]. Microglia
cells in the diseased retina are able to proliferate [19], se-
crete proinflammatory cytokines [20, 21], chemokines
[22], and reactive oxygen species [23], and they seem to
play an important role in retinal disease progression.
In the present study, prolonged systemic inflamma-
tion induced by repeated LPS injections led to activa-
tion of retinal microglia and infiltration of monocytes,
retinal edema, and accumulation of sub-retinal fluid
as signs of BRB breakdown. Moreover, a single LPS
injection triggered the production of a plethora of
inflammatory mediators in the retina and this
phenomenon was abolished after repeated injections.
In addition, the use of a colony-stimulating factor
1-receptor (CSF1-R) inhibitor, which we have previ-
ously shown to dramatically deplete retinal microglia
[24], provides evidence that the breakdown of the
BRB can be abrogated by suppression of the innate
immune response. These data suggest that resident
retinal microglia in combination with monocytes in-
vading from the circulation are responsible for the
breakdown of the BRB and that BRB integrity can be
preserved by inhibition of the CSF-1R.
Materials and methods
Animals
Adult (6–8 weeks of age) Balb/c and Cx3cr1gfp/+ mice,
hemizygous for the expression of green fluorescent
protein (GFP) under the endogenous Cx3c chemokine
receptor 1 (Cx3cr1) promoter, on a Balb/c back-
ground [25] were used for this study. Animals were
housed in groups of 2–5 under temperature and hu-
midity-controlled conditions in individually ventilated
cages with a 12-h light/12-h dark cycle. Mice were
anesthetized by intraperitoneal injection of 1 mg/kg
medetomidine (Dormitor 1 mg/mL, Provet AG, Lys-
sach, Switzerland) and 80 mg/kg ketamine (Ketalar 50
mg/ml, Parke-Davis, Zurich, Switzerland) for imaging.
Atipamezol 2.25 mg/kg (Antisedan 5 mg/mL, Provet
AG, Lyssach, Switzerland) was used to antagonize
medetomidine after the intervention. At the end of
the experiment, mice were euthanized by carbon di-
oxide (CO2) inhalation.
Systemic LPS challenge
Mice were intravenously injected (tail vein) with
150 μl lipopolysaccharides (LPS) from Escherichia coli
[1 mg/kg in 1x phosphate-buffered saline (PBS), pH
7.4; Sigma-Aldrich] for four consecutive days. Control
mice received intravenous injections of PBS instead of
LPS. Retinal imaging was performed at baseline (be-
fore LPS injection), day 4 (approximately 6 h after the
last LPS challenge) and day 7 (3 days after the last
LPS challenge). One group of mice (n = 4 Balb/c and
n = 8 Cx3cr1gfp/+ mice) was euthanized at day 4, and
a second group (n = 8 Cx3cr1gfp/+ mice) was eutha-
nized at day 7 immediately after the imaging session.
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Inhibition of colony-stimulating factor-1 receptor (CSF-1R)
with PLX5622
The CSF-1R inhibitor PLX5622 was incorporated into
the mouse chow (1200 ppm formulated in AIN-76A
standard rodent diet; Research Diets, Inc., New Bruns-
wick, NJ, USA, provided by Plexxikon, Inc.). One group
of Cx3cr1gfp/+ mice (n = 6) had ad libitum access to
PLX5622-chow 1 week before the LPS challenge and
until the end of the experiment, while a second group of
animals (n = 6) was fed with control chow (provided by
Plexxikon, Inc.). Microglia depletion by PLX5622 was
evaluated 1 week after the initiation of PLX5622 treat-
ment with autofluorescent imaging. LPS (1 mg/kg in
PBS) was administered intravenously immediately after
the imaging session for four consecutive days, and mice
were imaged approximately 6 h after the last LPS chal-
lenge and euthanized immediately after.
Imaging
Before and after the LPS challenge, mice were imaged
with spectral domain optical coherence tomography
(SD-OCT) for the evaluation of retinal structure, auto-
fluorescence imaging (AF) for the visualization of
GFP-positive cells, and fluorescein angiography (FA) for
the visualization of retinal vasculature using a Heidel-
berg Spectralis device (Heidelberg Engineering GmbH,
Heidelberg, Germany). Mice were anesthetized and
placed on a custom-made platform positioned on the
chin rest of the SD-OCT device. No contact lens was
used during image acquisition. Pupils were dilated with
a drop of tropicamide 0.5%/phenylephrine 2.5% (Hos-
pital Pharmacy, Inselspital, Bern, Switzerland), and
hydroxypropylmethylcellulose (Methocel 2%; OmniVi-
sion, Neuhausen, Switzerland) was applied to each eye
during imaging to keep the cornea hydrated. The infra-
red mode was used to focus on retinal vessels and AF
images were acquired with a 102° lens at high resolution
of 1536 × 1636 pixels. After examination of both eyes,
SD-OCT was performed using a 55° lens at a high reso-
lution of 1008 × 596 pixels in grid mode. In total, 43 to
61 images were acquired centered on the optic nerve
head. For fluorescein angiography, 50 μl of fluorescein
solution (Fluorescein 10% Faure; Novartis, Switzerland;
0.01% in PBS) were injected subcutaneously and images
were acquired with a 55° or a 102° lens to visualize the
vascular plexus.
Retinal whole mounts
At the end of the experiments, mice were euthanized
with CO2 inhalation and their eyes were removed. From
each mouse, one eye was used for retinal whole mounts
and the other one was used to obtain vertical retinal sec-
tions (see below). For retinal whole mounts, the eyes
were processed as reported elsewhere [26]. Retinas were
incubated overnight at 4 °C with isolectin IB4 from Grif-
fonia simplicifolia (GS-IB4; Alexa Fluor 647 conjugate;
1:100, ThermoFisher Scientific, Waltham, MA, USA) for
labeling of retinal vasculature, a rabbit polyclonal anti-
body against ionized calcium-binding adapter molecule
1 (anti-iba1 rabbit polyclonal antibody, 1:500, Wako Cat
#019-19741, Wako Pure Chemical Industries Ltd.,
Osaka, Japan) for labeling of microglia/macrophages,
and/or a chicken polyclonal antibody against GFP
(1:100, ab13970, Abcam, Cambridge, UK) for the label-
ing of microglia/macrophages in Cx3cr1gfp/+ mice. Ret-
inas were washed with 1x PBS 0.2% Triton X-100
(Sigma-Aldrich, St. Louis, MO, USA) and incubated with
the secondary antibodies goat anti-rabbit IgG (H&L)
Alexa Fluor 594 conjugate (1:1000, A27016, Thermo-
Fisher scientific, Waltham, Massachusetts, USA) for
Iba-1 and/or a pre-absorbed goat polyclonal antibody to
chicken IgY H&L (FITCH) (1:1000, ab7114, Abcam,
Cambridge, UK) for GFP. Retinas were then washed in
1x PBS 0.2% Triton X-100; four radial cuts were made
and tissues were flat-mounted on a slide having the
ganglion cell layer facing up. Whole mounts were
cover-slipped and examined under a confocal micro-
scope. Primary and secondary antibodies were diluted in
1x PBS, 0.2% Triton X-100, 5% normal goat serum
(NGS, X0907, DAKO AG, Wiesentheid, Germany).
Immunohistochemical studies
One eye from each euthanized mouse was fixed in 4%
paraformaldehyde (PFA, pH 7.4) for 24 h. Eyes were
processed for routine paraffin embedding, and slices of
5 μm were cut with a microtome (Leica Biosystems,
Muttenz, Switzerland) from the central retina including
the optic nerve head. Slides were deparaffinized, rehy-
drated, and endogenous peroxidase activity was blocked
by incubation with 0.5% H2O2 in methanol. Antigen re-
trieval was achieved by incubation in citrate buffer (10
mM, pH 6.0, 95 °C, 10 min). Slides were blocked for 30
min with 5% normal goat serum (NGS) in 0.01% Triton
X-100 and incubated with the anti-Iba-1 antibody (see
above) overnight at 4 °C. Slides were washed with PBS
and incubated with a biotinylated goat anti-rabbit IgG
antibody (1:1000; Vector labs, Burlingame, CA) for 60
min at room temperature. Slides were washed again and
incubated with Horseradish Peroxidase-Streptavidin
(1:1000; Vector labs, Burlingame, CA), for 60 min at
room temperature. Slides were treated with the
NovaRED Peroxidase (HRP) Substrate Kit (Vector
labs, Burlingame, CA) according to the manufacturer
instructions, washed in distilled water, counterstained
with hematoxylin and mounted in non-aqueous
mounting medium (Eukitt; O. Kindler GmbH & Co,
Freiburg, Germany).
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For the labeling of neutrophils and aquaporin 4
(AQP4), slides were treated as above, and after the anti-
gen retrieval, they were blocked for 30 min with 1x PBS,
5% NGS, 0.1% Triton X-100 and incubated overnight at
4 °C with a rabbit monoclonal antibody against myelo-
peroxidase (MPO, 1:1000, ab208670, Abcam, Cambridge,
UK) or a rabbit polyclonal antibody against AQP4
(1:500, AQP-014, Alomone labs, Jerusalem, Israel). For
the investigation of microglia proliferation in Cx3cr1gfp/+
mouse retinas, a rabbit polyclonal antibody against Ki67
(1:1000, Abcam, Cambridge, UK) was used in combin-
ation with the chicken anti-GFP (see above). Slides were
mounted with mounting medium containing DAPI
(Vector Laboratories, Burlingame, CA, USA), cover-
slipped, and examined under the microscope. The sec-
ondary antibodies goat anti-rabbit IgG (H&L), Alexa
Fluor 594 conjugate (1:1000, A27016, ThermoFisher
scientific, Waltham, Massachusetts, USA) and Alexa
Fluor 488 conjugate (1:1000, A11008, ThermoFisher sci-
entific, Waltham, Massachusetts, USA) were used for
the visualization of Ki67, and MPO or AQP4 staining,
respectively.
Microscopy
An epifluorescence microscope (Olympus BX60 micro-
scope; Olympus, Tokyo, Japan) was used for the examin-
ation of retinal sections. Retinal whole mounts were
imaged using an inverted Zeiss LSM 710 fluorescence
confocal microscope (Carl Zeiss, Oberkochen, Germany).
Z-stacks of 100.8 ± 15.1 μm (mean ± standard deviation
[SD]) with 5-μm interval were obtained and analyzed
with the ZEN system 2011 software (Carl Zeiss). Photo-
shop (Version 7.0, Adobe Systems, San Jose, CA, USA)
was used to adjust light and contrast. All final figures
were prepared in CorelDraw (Corel Corporation of
Ottawa, Canada).
Microglia quantification and retinal thickness
measurements
Retinal microglia (GFP+ cells) was quantified on the
whole area of each single AF image using the ImageJ
software [27] and the “Analyze particles” function as re-
ported elsewhere [28]. For the estimation of microglia
occupied area, color threshold was adjusted in retinal
AF images and the pixel areas of the binary mask was
calculated and expressed as a percentage of the total
pixel area. Retinal thickness in OCT volume scans was
measured in the four inner Early Treatment Diabetic
Retinopathy Study (ETDRS) subfields, using the Orion™
software (Voxeleron LLC, Pleasanton, CA, USA). Cor-
rection of the lines marking the Bruch’s membrane and
the inner limiting membrane were manually performed
before thickness measurements.
Protein extraction
In total, 36 Balb/c mice were used for protein extraction
and subsequent analysis of protein levels in retinas and
blood plasma using a mouse inflammation antibody
array-membrane kit (Abcam, Cambridge, UK). One
group of mice (n = 12) had ad libitum access to
PLX5622 chow for 1 week before the LPS challenge and
until the end of the experiment. A second group of mice
(n = 24) was fed with control chow for the whole dur-
ation of the experiment. PLX5622-fed and control mice
were challenged with LPS (1 mg/kg) and euthanized 12
or 24 h after the first LPS injection or 6 h after the
fourth daily LPS injection. For protein extraction, the
cornea and the lens were removed, the retina was mech-
anically detached from the remaining eyecup and placed
in lysis buffer [1x lysis buffer provided with the kit, 1
mM Na3VO4, protease inhibitor cocktail (Roche, Basel,
CH)]. Tissue homogenization was performed with a
Precellys 24 tissue homogenizer (Bertin Instruments,
Montigny-le-Bretonneux, France). Four retinas were
pooled as one sample. Homogenized tissues were incu-
bated for 30 min on ice before being centrifuged for 20
min at 13000 rpm at 4 °C. The supernatant was trans-
ferred into a clean tube, and total protein concentration
was determined using the Bradford assay.
Blood plasma preparation
Peripheral blood was collected from mice used for pro-
tein extraction (see above). Briefly, mice were intraperi-
toneally injected with a lethal dose of pentobarbital (≥
200 mg/kg; Esconarkon, Streuli Pharma AG, Uznach,
300 mg/ml) and blood was collected by cardiac punc-
ture, in tubes containing ethylenediaminetetraacetic acid
(EDTA) (pH 8, 0.5M), to prevent blood coagulation.
Blood samples were gently mixed and centrifuged for 10
min, at 2000 g and at 4 °C. The supernatant was col-
lected in new tubes and 5 μl of a 2x stock protease in-
hibitors cocktail (cOmplete ULTRA Tablets, EDTA-free;
Roche, Basel, CH) was added per 100 μl of plasma. Total
protein concentration of plasma samples was deter-
mined using the Bradford assay.
Mouse inflammation antibody array-membranes
Antibody array-membranes (Abcam, Cambridge, UK)
were processed according to manufacturer’s instructions.
Briefly, the membranes were blocked for 2 h in blocking
buffer (provided with the kit) and incubated with 500 μg
of total protein overnight at 4 °C. Membranes were ex-
tensively washed with wash buffer (provided with the
kit) and were incubated with 1 ml of biotin-conjugated
anti-cytokines (provided with the kit) in blocking buffer
overnight at 4 °C with gentle shaking. Membranes were
washed again and incubated with 1x HRP-conjugated
streptavidin (provided with the kit) for 2 h at room
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temperature. Chemiluminescence detection was per-
formed using detection buffers provided with the kit and
a Fusion Pulse Imaging System (Witec AG, Luzern, CH).
Densitometry analysis was performed using the “Protein
Array Analyzer” function of the ImageJ software [27].
The background was subtracted, and the signal was nor-
malized between different membranes using the positive
control spots.
Flow cytometry analysis
Cx3cr1gfp+/− mice treated with either four daily doses of
LPS (1 mg/kg) or equal volume of PBS were euthanized
approximately 6 h after the last LPS challenge, and their
retinas were used for flow cytometry analysis. Both ret-
inas of each mouse were analyzed as one sample. Retinas
were processed according to Ebneter et al. [8]. Before
antibody staining, single cells suspensions were incu-
bated with Zombie Red™ Fixable Viability Kit (Biolegend,
1:800) in Dulbecco’s phosphate-buffered saline (DPBS−/−,
ThermoFisher Scientific)/0.01% DNase I (Roche), for
detection of dead cells, according to the manufacturer’s
instructions. For antibody staining, the samples were
washed, re-suspended in flow cytometry buffer (5mM
EDTA, 20% FBS, 0.5% Na azide, in DPBS−/−/0.01% DNase
I) and incubated for 20min with an Fc blocker (Biolegend,
1:200). Microglia and macrophages were subsequently
stained with fluorescent-labeled antibodies against CD45
(30-F11, 1:400), CD11b (M1/70, 1:200) and MHC-II
(major histocompatibility complex class-II, AF6-120.1,
1:200), for 20min at 4 °C in the dark. Samples were
washed again and re-suspended in 0.1% PFA (pH 7.4) for
10min at 4 °C in the dark. The samples were washed two
times, re-suspended in flow cytometry buffer, and
analyzed. All washing steps involved addition of 1ml
DPBS−/−/0.01% DNase on each sample and centrifugation
at 500 g for 3min, at 4 °C.
Data were acquired with an LSR II Cytometer System
and the BD FACSDiva software (BD Biosciences, Allsch-
wil, Switzerland). The data were analyzed with the
Flowjo Single Cell Analysis Software V10 (TreeStar, Ash-
land, OR, USA). All antibodies were purchased from
Biolegend (San Diego, CA, USA).
Statistics
GraphPad Prism 5.0 software (GraphPad Software, Inc.,
San Diego, CA, USA) was used for the statistical ana-
lysis. The normal distribution of the different data sets
was evaluated using the Shapiro-Wilk normality test.
Statistically significant differences of GFP-positive cell
numbers or areas occupied by GFP-positive cells on AF
images were determined using repeated measures
one-way ANOVA followed by Tukey’s post hoc analysis.
For the comparison of the flow cytometry data, unpaired
t tests were used. Retinal thickness measurements were
compared using ordinary one-way ANOVA followed by
Tukey’s post hoc analysis. For the comparison of cyto-
kine/chemokine expression levels, ordinary one-way
ANOVA followed by Tukey’s post hoc analysis was used
for normally distributed data and Kruskal-Wallis test
followed by Dunn’s multiple comparison test was used
for data following non normal distribution. P values <
0.05 were considered statistically significant. The quanti-
fication data are presented as mean ± SD throughout the
manuscript and figures.
Results
Effect of systemic LPS treatment on blood-retina barrier
integrity
In vivo imaging of Balb/c mice with SD-OCT and FA,
before and after four daily injections of LPS as well as 7
days after the first LPS challenge (Fig. 1), revealed a nor-
mal retinal structure and retinal vasculature at baseline
(Fig. 1a–c) and accumulation of sub-retinal fluid at day
4 of LPS challenge (Fig. 1d–f ). At day 7, retinal structure
was comparable to the baseline (Fig. 1g–i). Leakage of
fluorescein was observed in fluorescein angiograms of
LPS-challenged mice at day 4 (Fig. 1k), suggesting dis-
ruption of the BRB, but not at day 7 (Fig. 1l).
Effect of systemic LPS challenge on microglia/
macrophages population in the retina
Microglia/macrophage populations in the retinas of
Cx3cr1gfp+/− mice were monitored in vivo with AF im-
aging before and after the LPS challenge (Fig. 2a). At
baseline, the GFP+ cells were normally distributed
(Fig. 2b), while accumulation of microglia/macrophages
around retinal vessels was observed at day 4 of systemic
LPS challenge (Fig. 2c). This was reversed 3 days after
the last LPS injection (Fig. 2d). Retinal whole mounts
stained with GFP substantiated this observation
(Fig. 2e–j). The number of GFP-positive cells was in-
creased by 18% at day 4 of LPS challenge (Fig. 2k; 221.3
± 28.66 cells per mm2 at day 4 compared to 187.5 ±
23.83 cells per mm2 counted at baseline, ***p < 0.001,
n ≥ 8 retinas per time point) and remained elevated
3 days after the last LPS challenge (Fig. 2k; 211.6 ± 34.23
cells per mm2, **p < 0.01; n ≥ 8 retinas). Microglia/mac-
rophages occupied a larger retinal area at day 4 of LPS
challenge (Fig. 2l; ***p < 0.001, n ≥ 8 retinas), which de-
creased 3 days later (Fig. 2 l; *p < 0.05, n ≥ 8 retinas)
while still increased compared to baseline (Fig. 2l; ***p <
0.001, n ≥ 8 retinas). Iba-1-positive microglia/macro-
phages were mainly found in the inner and outer plexi-
form layer of the control retina (Fig. 3a). Four days after
repetitive LPS challenges, Iba-1-positive cells could be also
detected in the sub-retinal space (Fig. 3b; red arrows) and
in the distal ONL (Fig. 3b, c; yellow arrows). Iba-1-positive
cells migrating from the inner retina towards the ONL
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were also detected (Fig. 3c; red arrow). Examination of ret-
inal whole mounts by confocal microscopy revealed a
ramified morphology of GFP-positive cells in the control
retinas (Fig. 3d), while in LPS-challenged-mice an
amoebic-like morphology as signs of activation was ob-
served (Fig. 3e).
Quantification of microglia/macrophages with flow
cytometry
Flow cytometry was performed on the retinas of
Cx3cr1gfp+/− mice treated with either LPS (1 mg/kg)
or PBS for four consecutive days, approximately 6 h
after the last LPS injection. After selection of single-
live cells, the GFP+CD11b+ population has been se-
lected and further gated as CD45low (microglia) and
CD45hi (macrophages) (Fig. 4a). A population of
GFP−CD11b+ cells was detected in the LPS group,
most probably representing neutrophils and/or den-
dritic cells (Fig. 4a, bottom left panel). A few
GFP+CD11b+ macrophages were present in the con-
trol retinas, while their number was elevated after 4
LPS challenges (Fig. 4a, right top and bottom panels).
A higher number of microglia and macrophages
expressed the activation marker MHC-II after the LPS
challenge compared to the control retinas (Fig. 4b).
Quantification of different cell populations revealed
Fig. 1 Disruption of the blood-retina barrier in LPS-challenged mice. Infrared images (a, d, g) and vertical B-scans (b, e, h), at baseline (a, b), at
day 4 of the LPS challenge (d, e), and at day 7 after the first LPS challenge (g, h) in Balb/c mice, revealed accumulation of sub-retinal fluid after 4
daily systemic injections of LPS. At higher magnification individual retinal layers can be seen at baseline (c), at day 4 of the LPS challenge (f), and
at day 7 after the first LPS challenge (i). Sub-retinal fluid was accumulated in LPS-treated mice at day 4 (f). Fluorescein angiograms at baseline (j), at day
4 of the LPS challenge (k), and at day 7 after the first LPS challenge (l) revealed fluorescein leakage in LPS-treated mice at day 4 (k). Arrows
correspond to the leakage area. Location of B-scans in b, e, and h is indicated with the middle line in a, d, g, respectively. One
representative retina out of ≥ 8 is presented for each time point. A, artery; INL, inner nuclear layer; IPL, inner plexiform layer; OD, optic disk;
ONL, outer nuclear layer; OPL, outer plexiform layer; PIS/POS, photoreceptor inner segments/photoreceptor outer segments; RNFL, retinal nerve fiber layer;
RPE, retinal pigment epithelium; V, vein
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Fig. 2 (See legend on next page.)
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elevated numbers of GFP+CD11b+, GFP+CD11b+CD45low,
and GFP+CD11b+CD45hi cells in the retinas of the
LPS-challenged mice (Fig. 4c–e, respectively; **p < 0.01,
***p < 0.001 compared to control; unpaired t test).
MHC-II was used as an activation marker and the num-
bers of GFP+CD11b+CD45lowMHC-II+ microglia and
GFP+CD11b+CD45hiMHC-II+ macrophages were quanti-
fied. Statistically significant increase of microglia and mac-
rophages activation was observed in the LPS group
(Fig. 4f, g, respectively; **p < 0.01 compared to control; un-
paired t test). The majority of GFP+CD11b+ cells in the
LPS retina corresponded to microglia and 14.8% of them
(13% of total GFP+CD11b+ cells) expressed the activation
marker MHC-II. Macrophages represented almost 12% of
the total GFP+CD11b+ population and about 37.5% of
them (4.5% of total GFP+CD11b+ cells) were MHC-II+
(Fig. 4h).
Effect of the CSF-1 receptor inhibitor PLX5622 on
microglia population in the retina
In vivo AF imaging and staining of retinal whole mounts
with GFP, in Cx3cr1gfp+/− mice fed with the CSF-1R in-
hibitor PLX5622, revealed dramatic differences in the
number of GFP-positive cells before and after the initi-
ation of PLX5622 diet (Fig. 5d, e). The number of
GFP-positive cells was diminished by approximately 97%
after 7 days of PLX5622 diet (Fig. 5e, i, ***p < 0.001; BL,
189.2 ± 12.4 cells per mm2; PLX5622 day 7, 5.8 ± 2.0
(See figure on previous page.)
Fig. 2 Accumulation of microglia/macrophages around retinal vessels in LPS-challenged mice. Experimental setup (a) and representative
autofluorescence images of microglia/macrophages in the retina at baseline (b), after the fourth LPS injection (c) and 3 days after the last
LPS injection (d). GFP-positive cells were identified as white signal on the autofluorescence images. One representative retina out of ≥ 8
is presented for each time point. Retinal whole mounts from untreated (e, control) and LPS-treated Cx3cr1gfp/+ mice stained with GFP at day 4 (f) and
at day 7 (g) after the first LPS injection. One representative retina out of ≥ 4 is presented for each time point. Higher magnification of the delineated
areas in e, f, and g are depicted in h, i, and j, respectively. The numbers of GFP-positive cells were elevated in the retina at day 4 of the LPS challenge
and 3 days after the last LPS challenge, compared to the baseline (k; **p < 0.01, ***p < 0.0001; n = 13 eyes for each time point; repeated
measures one-way ANOVA followed by Tukey’s post hoc analysis). The area occupied by microglia cells in the retina was elevated after
the LPS challenge and was decreased 3 days after the termination of the inflammatory stimulus (l; n = 14 eyes for each time point; *p < 0.05, **p < 0.01,
***p < 0.001; repeated measures one-way ANOVA followed by Tukey’s post hoc analysis). Arrows represent the location of retinal vessels. Scale bars:
500 μm (e, f, g); 200 μm (h, i, j)
Fig. 3 Activation and migration of retinal microglia/macrophages after LPS challenge in Cx3cr1gfp/+ mice. In control retinas (a), Iba-1-positive cells
were mainly found in the inner and outer plexiform layer (IPL and OPL, respectively). In LPS-challenged retinas (b, c), Iba-1-positive microglia/macrophages
were also detected in the proximity of the sub-retinal fluid accumulation (red arrows in b) and in the distal ONL (yellow arrows in b and c). Iba-1-positive
cells migrating towards the outer retina were also detected (red arrow in c). In control retinal whole mounts, GFP-positive microglia cells
have a ramified morphology typical for resting microglia (d). After LPS challenge, activated GFP-positive cells with retracted processes and
round cytosol were detected in the retina (e). One representative retina out of ≥ 4 is presented for each time point. Scale bars: 100 μm.
GCL, ganglion cell layer; IPL, inner plexiform layer; OPL, outer plexiform layer; RPE, retinal pigment epithelium
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Fig. 4 Flow cytometry analysis of different microglia/macrophages populations in the retina after systemic LPS challenge. Microglia/macrophages were
gated as GFP+CD11b+ cells (a, left panel) and were further gated as CD45low microglia and CD45hi macrophages (a, right panel). MHC-II expression in
microglia and macrophages was increased in the LPS-challenged group (b). The numbers of GFP+CD11b+ microglia/macrophages (c, ***p< 0.001,
unpaired t test), GFP+CD11b+CD45low microglia (d, **p< 0.01, unpaired t test) and GFP+CD11b+CD45hi macrophages (e, ***p< 0.001, unpaired t test) were
elevated in the LPS group. Microglia (f, **p< 0.01, unpaired t test) and macrophages (g, **p< 0.01, unpaired t test) activation was also increased in the LPS
group. The pie chart depicts the composition of the GFP+ cells in the retina after four consecutive LPS challenges (h)
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cells per mm2, n ≥ 8 retinas per time point). Further-
more, the area occupied by microglia was significantly
reduced by PLX5622 compared to baseline (Fig. 5j).
Challenging of PLX5622-fed mice with LPS did not yield
any statistically significant increase in the number of
GFP-positive cells or the occupied area (Fig. 5f, h, i, j,
12.9 ± 7.9 cells per mm2, n ≥ 8 retinas per time point). In
all mice fed with PLX5622 throughout the experiment,
no fluorescein leakage (Fig. 6c, d) or accumulation of
sub-retinal fluid (Fig. 6k-p) was observed. Moreover, ret-
inal swelling that was observed after four daily LPS in-
jections was totally abrogated by PLX5622 (Fig. 6q, **p
< 0.01, ***p < 0.001, n ≥ 7 retinas).
Effect of systemic LPS challenge on inflammatory
cytokine and chemokines levels in the retina
The relative expression of inflammatory mediator levels,
which were significantly changed compared to control
retinas, is summarized in Table 1. A pronounced in-
crease of more than 20 fold was detected in several che-
mokines (e.g., CCL3, CCL12, CRG-2), proinflammatory
cytokines (e.g., IL-6, IL-9, IL-17) and growth factors
(e.g., IGFBP-6, GM-CSF), 24 h after the first systemic
LPS insult. Less but still pronounced increase was ob-
served in several other pro- (e.g., IL-1α, IL-12p70, IL-3,
TNF-α) and anti-inflammatory cytokines (e.g., IL-13,
IL-4) 24 h after a single LPS challenge. Repetitive LPS
challenge (4 daily injections) abolished the increase in
most of cytokine levels in the retina, while it did lead to
an increase of basic fibroblast growth factor (bFGF).
PLX5622 abolished the LPS-induced increase on cyto-
kines expression with only few exceptions (e.g., CXCL1,
I-CAM, bFGF).
Effect of systemic LPS challenge on inflammatory
cytokine and chemokines levels in the peripheral blood
plasma
The expression of 23 cytokines and chemokines was ex-
amined in the peripheral blood plasma from LPS-chal-
lenged mice in the absence or presence of PLX5622
(Table 2). Twelve [10] hours after a single LPS challenge
only granulocyte colony-stimulating factor (G-CSF)
levels were elevated in the blood plasma and remained
elevated at 24 h and after 4 daily LPS injections (96 h).
At 24 h, an increase on MMP-3 protein levels was de-
tected, and after repeated LPS exposures, CXCL1,
G-CSF, IL-4, and MMP-3 were all increased compared
to control. The presence of PLX5622 led to a decrease
of IL-4 levels below control levels at 12 h while IL-4
levels were gradually increased above control levels at
96 h. A statistically significant increase in the levels of
CXCL1, G-CSF, and MMP-3 was induced in the pres-
ence of PLX5622 compared to the control-fed animals
challenged with LPS. No differences were observed in
the levels of insulin growth factor-1 (IGF-1), monocyte
chemoattractant protein 1 (MCP-1), transforming
growth factor beta (TGF-beta), interleukin-10 (IL-10),
IL-1α, IL-1β, IL-6, macrophage-CSF (M-CSF), tumor ne-
crosis factor-α (TNF-α), macrophage inflammatory
protein-1α (MIP-1α), MMP-2, Fas ligand, fractalkine,
CXCL1, interferon-γ (IFN- γ), or CCL17.
Effect of systemic LPS challenge on microglia
proliferation and neutrophils recruitment into the retina
No immunoreactivity of the proliferation marker Ki67
was observed in the control retinas (Fig. 7a), while Ki67
was expressed and co-localized with GFP in the retinas
of LPS-challenged mice (Fig. 7b). Isolated proliferating
microglia cells were still observed in the retinas of
PLX5622-fed mice challenged with LPS (Fig. 7c). The
neutrophil marker myeloperoxidase (MPO) was absent
in the control eyes (Fig. 7d). MPO positive cells were
found in the retina and choroid of the LPS-challenged
mice (Fig. 7e) while in PLX5622-fed LPS-challenged
mice, MPO-positive neutrophils were exclusively local-
ized in the choroid (Fig. 7f ).
Discussion
Accumulation of sub-retinal fluid is commonly seen in
retinal pathologies such as AMD, DR, or uveitis, and the
assumed cause is generally agreed to be a breakdown of
the outer BRB. The presence of sub-retinal fluid has
been correlated with accumulation of activated microglia
cells in the sub-retinal space [29, 30]. In the present
(See figure on previous page.)
Fig. 5 Depletion of retinal microglia using a CSF-1R tyrosine kinase inhibitor (PLX5622). Cx3cr1gfp/+ mice were imaged at baseline, were fed with
control chow or PLX5622 chow for the rest of the experiment, and were injected with LPS at day 7 after the initiation of the diet. LPS was injected
intravenously for four consecutive days and retinas were analyzed after the last LPS injection. Representative autofluorescence images of
LPS-challenged Cx3cr1gfp/+ mice fed with control or PLX5622 chow at baseline (a, d, respectively), 7 days after the initiation of the diet (b,
e, respectively) and after 4 daily LPS injections (c, f, respectively). In retinal whole mounts of LPS-challenged mice fed with control chow,
GFP-positive cells were observed throughout the retina and were accumulated around retinal vessels (g). Incorporation of PLX5622 into
the mouse chow led to a reduction of GFP-positive cells in the retina at day 4 of the LPS challenge (h). One representative retina out of
≥ 8 is presented for each time point. Counting of GFP-positive cells on autofluorescence images showed dramatic reduction of the
number of GFP-positive cells (i, n = 5 mice; ***p < 0.001; repeated measures one-way ANOVA followed by Tukey’s post hoc analysis), as
well as the area they occupied (j, n = 6 mice; ***p < 0.001; repeated measures one-way ANOVA followed by Tukey’s post hoc analysis),
after PLX5622 treatment. Scale bars: 500 μm
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study, a prolonged systemic inflammatory stimulus with
LPS led to increased vascular permeability, retinal swell-
ing, and accumulation of sub-retinal fluid in Balb/c mice
(Fig. 1 and Fig. 6q), indicating breakdown of the outer
BRB. The BRB is a multicellular vascular structure that
separates the neurosensory retina from the peripheral
blood circulation and regulates the flux of water and
ions into the retina [31], possibly via a family of water
membrane-channel proteins, the aquaporins (AQP) [32,
33]. This barrier function prevents leakage of fluid and
hydrophilic solutes into the retina and is therefore vital
for visual function. The BRB consists of two compo-
nents; the inner blood-retina barrier constituted by the
tight junctions between neighboring retinal endothelial
cells, restricting the diffusional permeability of the ret-
inal endothelial layer, and the outer blood-retina barrier,
which is formed by the tight junctions between neigh-
boring RPE [33]. The tight junctions of the RPE separate
the neural retina from the fenestrated choriocapillaries
and are crucial in maintaining retinal adhesion. In our
model, the increase in vascular permeability was transi-
ent and was accompanied by accumulation of
GFP-positive cells around retinal vessels of Cx3cr1gfp/+
LPS-challenged mice (Fig. 2). Thus, we suspect that tem-
porary failure of tight junctions occurred. Moreover,
AQP4 expression was not altered in the LPS-challenged
mice compared to the control mice (Additional file 1:
Figure S1).
In most experimental studies, microglia in the
CNS are activated by a single dose of LPS which
may bear little resemblance of what occurs in sys-
temic inflammation in humans where bacterial prod-
ucts and toxins can persist for some time. Prolonged
LPS exposure may result in permanent microglia ac-
tivation and increase in vascular permeability. In this
line, intestinal-derived endogenous endotoxins such
as LPS [34] have been implicated to play an import-
ant role in the development of chronic inflammatory
conditions such as atherosclerosis which is associated with
AMD [35]. In the present study, we show that repeated
exposure to LPS leads to activation of microglia/macro-
phages in the retina (Figs. 2, 3, and 4) peaking at day 4
after the first LPS challenge. Microglia/macrophages num-
bers were still elevated 3 days after the last LPS injection
(Fig. 2), although sub-retinal fluid and fluorescein leakage
was not observed at that time point (Fig. 1). Both, micro-
glia as well as macrophage numbers were higher at day 4
after LPS challenge, suggesting on the one hand prolifera-
tion of microglia as evident by staining with Ki67 (Fig. 7),
as well as migration of circulatory macrophages into the
retina revealed by flow cytometry (Fig. 4).
Systemic LPS administration can lead to production of
proinflammatory cytokines, such as tumor necrosis fac-
tor alpha (TNF-α) or interleukin-1β (IL-1β) from acti-
vated microglia in the brain [36, 37] and retina, while it
also contributes to the disruption of the blood-brain bar-
rier (BBB) and BRB [38–41]. In line with these findings,
we observed a robust increase in a plethora of inflamma-
tory cytokines, including TNF-α, IL-1β, and IFN-γ in the
retinas of LPS-challenged mice, 1 day after the challenge
(Table 1). However, this increase was transient since
after four repetitive LPS injection only basic fibroblast
growth factor (bFGF) and VCAM-1 levels were elevated,
while the rest of the cytokines examined did not differ
from the levels detected in the retinas of unchallenged
mice (Table 1).
Repeated peripheral LPS injection can induce
so-called endotoxin tolerance [42]. LPS tolerance is
thought to result from a hyporesponsive state of
microglia/macrophages resulting from receptor
desensitization [43, 44] and downregulation of in-
flammatory cytokine gene expression [45]. However,
it has been shown that some inflammatory genes,
such as CCL5, CXCL9, and CCL8, remain inducible
even after repeated LPS injections [46], while others,
such as TNF-α, IL-6, IL-12, IL-1β, CCL3, CCL4, and
CXCL10, are downregulated upon LPS re-stimula-
tion. On the other hand, increased secretion of an-
giogenic factors such as VEGF and bFGF can be
detected in tissues after chronic inflammation [47], and
this is associated with accumulation of more leukocytes
and injury aggravation [48].
The synthesis of proinflammatory cytokines in the
central nervous system after peripherally injected LPS
(See figure on previous page.)
Fig. 6 Inhibition of LPS-induced BRB disruption and retinal swelling using a CSF-1R tyrosine kinase inhibitor (PLX5622). Representative fluorescein
angiograms of LPS-challenged Cx3cr1gfp/+ mice fed with control chow (a, b) or PLX5622 chow (c, d), before (a, c for control and PLX5622, respectively)
and after four daily injections of LPS (b, d for control and PLX5622, respectively). In mice fed with the PLX5622 chow, no fluorescein
leakage is observed at day 4 of the LPS challenge (d). Vertical B-scans of mouse retinas fed with control (e–j) or PLX5622 chow (k–p) at
baseline (e–g and k–m for control and PLX5622, respectively) and after the fourth LPS injection (h–j and n–p for control and PLX5622,
respectively). The areas of the B-scans are indicated with lines in the infrared images. Magnifications of the areas inside the white boxes
are presented in g, j, m, and p. After 4 days of LPS injections, accumulation of sub-retinal fluid was present in the retinas of control-fed
mice (h–j), while PLX5622-fed mice had a normal retinal structure with no accumulation of sub-retinal fluid (n–p). One representative
retina out of ≥ 8 is presented for each time point. Total retinal thickness was increased at day 4 of the LPS challenge compared to the
baseline (q, **p < 0.01, ***p < 0.001, n = 14 eyes for each time point; ordinary one-way ANOVA followed by Tukey’s post hoc analysis),
while PLX5622 prevented retinal swelling
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has been demonstrated by several studies [49–51] and
is further supported by data showing that peripherally
released cytokines cannot pass through the intact
BBB or BRB [52–54]. Here, BRB breakdown was evi-
dent after four but not one LPS challenge. In periph-
eral blood plasma, only G-CSF was upregulated at the
acute phase (Table 2; 12 and 24 h after the first LPS
challenge), while after four repetitive LPS injections
elevated levels of CXCL1, G-CSF, IL-4, and MMP-3
were detected. Thus, given that the BRB is intact 1
day after the first LPS challenge, we speculate that
the robust increase in cytokine levels in the retina
represents topical production of cytokines, either from
activated microglia/macrophages or from activation of
the TRL4 receptors in RPE or retinal endothelial
cells [55].
To investigate the role of resident microglia on the
LPS-induced phenotype, we employed the highly
Table 1 Effect of LPS and LPS + PLX5622 in cytokine levels in
the mouse retina
24 h 96 h
LPS LPS + PLX5622 LPS LPS + PLX5622
Chemokines
CCL2 19.1*** 1.46### 1.13 1.24***#
CCL3 22*** 1.32### 0.88 0.85
CCL5 2.32*** 0.48### 0.84 0.85
CCL9 2.51** 0.59### 0.98 0.97
CCL11 7.73*** 0.55### 0.90 0.92
CCL12 21.65*** 0.76### 1.05 0.99
CCL17 20.07*** 0.94### 0.94 1.12
CCL19 10.49*** 0.69### 0.94 1.05
CCL20 12.63*** 1.16### 0.83 1.03
CCL24 8.15*** 0.60### 1.05 1.0
CCL27 10.70*** 0.67### 0.92 1.07
CRG-2 35.83*** 1.34### 0.73 0.96
CX3CL1 17.89*** 0.84### 0.85 0.83
CXCL1 6.34*** 3.16*### 1.06 1.10
CXCL2 8.61*** 0.78### 1.04 1.12
CXCL4 9.81*** 0.73### 1.07 1.10
CXCL5 8.16*** 0.99### 0.96 1.03
CXCL9 10.51*** 0.66### 0.81 0.83
CXCL12 15.65*** 0.92### 0.85 1.02
CXCL13 13.3*** 0.76### 0.86 0.96
CXCL16 7.89*** 0.72### 0.97 1.02
XCL1 14.74*** 1.09### 1.09 1.11
Growth factors
bFGF 0.87 1.16### 3.38* 1.33#
IGFBP-3 11.17*** 0.77### 0.91 1.11
IGFBP-5 8.79*** 0.64### 0.75 0.77
IGFBP-6 24.18*** 1.28### 0.86 0.90
G-CSF 11.25*** 2.45### 0.74 0.78
GM-CSF 25.42*** 1.04### 0.87 0.95
M-CSF 10.22*** 0.8### 1.05 1.17
VEGF 10.73*** 0.68### 0.78 0.8
TNF superfamily
CD30 40.00*** 2.60### 0.83 0.88
CD30 L 23.08*** 1.10### 0.70 0.85
CD40 67.50*** 3.25### 0.94 1.08
Fas ligand 5.48*** 0.59### 0.71 0.76
sTNFRI 5.06*** 0.91### 0.89 0.93
sTNFRII 8.39*** 0.86### 0.99 0.96
TNF-α 14.46*** 0.77### 1.65 0.74
Table 1 Effect of LPS and LPS + PLX5622 in cytokine levels in
the mouse retina (Continued)
24 h 96 h
LPS LPS + PLX5622 LPS LPS + PLX5622
cell adhesion molecules
I-CAM 1.40 3.29***### 1.04 1.27
VCAM-1 1.56* 0.62### 1.58** 1.42
L-selectin 7.77*** 0.72### 0.81 0.91
P-selectin 12.67*** 0.92### 0.94 1.00
Proinflammatory cytokines
IFN-γ 21.94*** 1.25### 0.81 0.86
IL-1α 9.05*** 0.73### 0.99 0.56*#
IL-1β 16.73*** 0.8### 0.85 0.98
IL-3 11.76*** 0.3### 0.78 0.75
IL-3 Rb 11.62*** 0.59### 0.92 0.8
IL-6 25.67*** 1.22### 0.84 0.83
IL-9 27.91*** 1.17### 0.85 0.82
IL-12 p70 16.26*** 0.78### 1.00 1.12
IL-17 29.23*** 1.13### 0.90 1.06
Leptin 14.70*** 0.5### 0.85 1.04
Leptin R 20.01*** 0.67### 0.96 1.02
TCA-3 10.25*** 0.72### 1.12 1.12
TIMP-1α 3.07*** 0.70### 0.94 0.86
Anti-inflammatory cytokines
IL-4 17.36*** 0.73### 1.21 1.22
IL-5 28.83*** 1.56### 0.79 0.83
IL-10 42*** 1.05### 1.08 1.14
IL-13 19.16*** 0.88### 0.90 0.95
All data are normalized to control retinas. *p < 0.05, **p < 0.01, ***p < 0.001
compared to control; #p < 0.05, ###p < 0.001 compared to LPS
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selective CSF-1R inhibitor PLX5622, which has been
previously shown to deplete microglia in the CNS [24,
56]. Accumulation of sub-retinal fluid and retinal swell-
ing were completely abrogated by PLX5622 (Fig. 6), sug-
gesting that the observed breakdown of the BRB after
systemic LPS exposure is at least partially mediated by
retinal microglia or microglia astrocyte interactions. LPS
has been shown to be a strong inducer of astrocytes in
the retina [38] and reactive astrocytes have been sug-
gested to play active roles in modulating BRB permeabil-
ity by release of cytokines such as interleukin-6 (IL-6)
and IL-1β [57, 58] and chemokines, such as CX3CL1
and CCL2 [59], while they can be directly activated by
LPS via TLR4 receptors [60, 61].
In our study, in the presence of PLX5622, the majority
of cytokines induced by LPS returned to control levels,
except for a moderate increase on the levels of CCL2,
CXCL1, and I-CAM and a decrease in the levels of
IL-1α (Table 1). In the blood plasma, the presence of
PLX5622 led to elevated levels of CXCL1 compared
to LPS, a cytokine that is associated with neutrophil
and macrophage maturation and migration [62]. In
the present study, we did observe neutrophil accumu-
lation in the choroid of LPS-challenged mice with or
without PLX5622 treatment (Fig. 7), while neutrophils
were also found within the retinas of LPS-challenged
mice but not PLX5622-fed LPS-challenged mice. Due
to the preserved integrity of the BRB in the
PLX5622-fed mice (Fig. 6), the above suggest that
neutrophils are invading into the retina through the
disrupted BRB but they do not play a major role in
mediating the BRB breakdown induced by LPS.
As mentioned above, PLX5622 has been shown to ef-
fectively deplete microglia in the retina and the brain
[24, 56] with only modest effects on circulating mono-
cytes and on macrophage numbers in other tissues of
wild-type mice [63]. However, in vitro studies have
shown that blockade of CSF-1R in bone marrow-derived
macrophages renders them resistant to LPS-induced ac-
tivation [64]. Based on these studies and given the
Table 2 Effect of LPS and LPS + PLX5622 in cytokine levels in the blood plasma
12 h 24 h 96 h
LPS LPS + PLX5622 LPS LPS + PLX5622 LPS LPS + PLX5622
CXCL1 1.14 1.40 1.69 4.18***### 2.20*** 5.02**
G-CSF 12.95*** 9.76***# 21.94*** 30.59***## 6.49*** 22.72***##
IL-4 0.88 0.43** 1.16 1.15 10.31*** 16.85***
MMP-3 0.92 0.94 1.82* 3.64***## 8.06** 27.62***###
All data are normalized to control plasma samples.*p < 0.05, **p < 0.01, ***p < 0.001 compared to control; #p < 0.05, ##p < 0.01, ###p < 0.001 compared to LPS
Fig. 7 Microglia/macrophages proliferation and neutrophils infiltration upon LPS challenge in the absence or presence of PLX5622. No immunoreactivity
of the proliferation marker Ki67 was detected in the control retinas (a). Ki67 was co-localized with GFP in retinas of LPS-challenged control-fed (b) or PLX-
fed mice (c). The neutrophil marker myeloperoxidase (MPO) was absent from the retina and choroid of unchallenged mice (d). In LPS-challenged mice,
MPO was detected into the retina and choroid (e), while in the PLX5622-fed LPS-challenged mice MPO was detected in the choroid (f) but not into the
retina. One representative retina out of five is presented for each group. Scale bars: 100 μm. GCL, ganglion cell layer; INL, inner nuclear layer, ONL, outer
nuclear layer
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importance of CSF-1R signaling in the differentiation,
proliferation, and activation of monocytes [65, 66], one
could speculate that PLX5622 may not only affect
microglia cell viability in the CNS but also peripheral
monocytes’ response to the LPS stimulus, which is sub-
ject to further investigation.
Conclusion
Taken together, the present study provides a useful and
highly reproducible model for the study of microglia/
macrophage dynamics in retinal diseases influenced by
systemic inflammation. Reversal of the LPS-induced
phenotype by the CSF-1R inhibitor PLX5622 suggests
that microglia and/or infiltrating macrophages partici-
pate in the breakdown of the BRB and the accumulation
of sub-retinal fluid during chronic inflammation, render-
ing the regulation of these cells activation a potentially
important therapeutic target for retinal disorders where
the integrity of the BRB is compromised. However,
whether the reduction in cytokine levels and the lack of
overt BRB breakdown in PLX5622-fed mice is a direct
consequence of the absence of microglial interaction
with the BRB, the lack of microglia-mediated astrocyte
activation or the failure of monocytes activation remains
to be investigated.
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